JP6320379B2 - Cdk4/6阻害剤およびb−raf阻害剤の組合せ医薬 - Google Patents
Cdk4/6阻害剤およびb−raf阻害剤の組合せ医薬 Download PDFInfo
- Publication number
- JP6320379B2 JP6320379B2 JP2015524444A JP2015524444A JP6320379B2 JP 6320379 B2 JP6320379 B2 JP 6320379B2 JP 2015524444 A JP2015524444 A JP 2015524444A JP 2015524444 A JP2015524444 A JP 2015524444A JP 6320379 B2 JP6320379 B2 JP 6320379B2
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- combination
- inhibitor
- compound
- raf
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Reproductive Health (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
またはそれらの薬学的に許容される塩(以下、それぞれ、化合物Cおよび化合物Dと称される)、ならびにそれらの全体が参照により本明細書に組み込まれる、WO05/051906、WO05/023251、WO03/077855、US20050049419およびUS7235537に記載された、増殖性疾患の治療のためのMEK1/2阻害剤としてのN3−アルキル化ベンズイミダゾールおよび他の類似のヘテロ環式誘導体を包含する化合物が含まれる。
(a)式
のCDK4/6阻害剤またはその薬学的に許容される塩(以下、化合物Aと称される)と、
(b)式
のB−Raf阻害剤またはその薬学的に許容される塩(以下、化合物Bと称される)と
(c)任意にMEK1/2阻害剤と
を含む治療的な組合せに関する。
(a)式
のCDK4/6阻害剤またはその薬学的に許容される塩と、
(b)式
のB−Raf阻害剤またはその薬学的に許容される塩と
を含む、治療的な組合せに関する。
(a)式
のCDK4/6阻害剤またはその薬学的に許容される塩と、
(b)式
のB−Raf阻害剤またはその薬学的に許容される塩と、
(c)MEK1/2阻害剤と
を含む治療的な組合せに関する。
化合物B−感受性原発性ヒトメラノーマHMEX1906異種移植片における化合物Aの感受性および化合物Aと化合物Bとの組合せ効力を評価する。それぞれの薬剤が前の試験で腫瘍静止または退縮を誘導したので、現試験の目標は、本発明の組合せによる処置後の再増殖までの時間を調査することである。
目的:原発性ヒトメラノーマ(BRAF変異体)HMEX2613異種移植片における化合物A、化合物B、および化合物Aと化合物Bとの組合せに対する応答の持続性を評価する。現試験の目標は、単剤および本発明の組合せによる処置後、500mm3に再増殖するまでの時間を調査することである。
目的:5mg/kgの化合物Bの存在下で増殖しているHMEX1906原発性メラノーマモデル、および5mg/kgの化合物Bに耐性であるHMEX1906原発性メラノーマモデル(HMEX1906−R5)における本発明の組合せの効力を評価する。
群:10匹マウス/群、経路PO、投与容量0.2mL
群1:ビヒクル、0mg/kg、1日2回×14
群2:化合物A、250mg/kg、1日1回×21
群3:化合物B、5mg/kg、1日2回×21
群4:化合物A、250mg/kg、1日1回×21+化合物B、5mg/kg、1日2回×21
材料および方法−化合物原液は、DMSO中で最終濃度10mMにて調製する。作業原液は、適当な細胞培地中で3倍増分にて連続的に希釈して、化合物Bおよび化合物Dについて2.7μMから1.2nM、化合物Aについて10μMから4.6nMの範囲の最終アッセイ濃度を得る。
以下に、本願の当初の特許請求の範囲に記載された発明を付記する。
[1] 同時、個別または逐次投与のための、
(a)式
のCDK4/6阻害剤またはその薬学的に許容される塩と、
(b)式
のB−Raf阻害剤またはその薬学的に許容される塩と
を含む、組合せ医薬。
[2] MEK1/2阻害剤をさらに含む、[1]に記載の組合せ医薬。
[3] 前記MEK1/2阻害剤が、式
の化合物またはその薬学的に許容される塩である、[1]に記載の組合せ医薬。
[4] 治療を必要としている対象における増殖性疾患の治療において使用するための、[1]、[2]または[3]のいずれかに記載の組合せ医薬。
[5] 増殖性疾患の治療のための薬剤の調製において使用するための、[1]、[2]または[3]のいずれかに記載の組合せ医薬。
[6] 前記増殖性疾患が、メラノーマ、肺がん(非小細胞肺がん(NSCLC)を含む)、大腸がん(CRC)、乳がん、腎がん、腎細胞癌(RCC)、肝がん、急性骨髄性白血病(AML)、骨髄異形成症候群(MDS)、甲状腺がん、膵がん、神経線維腫症、または肝細胞癌である、[4]に記載の組合せ医薬。
[7] 前記増殖性疾患が、B−Raf変異によって特徴付けられる、[6]に記載の組合せ医薬。
[8] 増殖性疾患の治療のための薬剤の製造のための、[1]、[2]または[3]のいずれかに記載の組合せの使用。
[9] ヒト患者における増殖性疾患を治療する方法であって、[1]、[2]または[3]のいずれかに記載の組合せ医薬の治療有効量を前記患者に同時、個別または逐次投与することを含む、方法。
[10] 前記増殖性疾患が、メラノーマ、肺がん、大腸がん(CRC)、乳がん、腎がん、腎細胞癌(RCC)、肝がん、急性骨髄性白血病(AML)、骨髄異形成症候群(MDS)、非小細胞肺がん(NSCLC)、甲状腺がん、膵がん、神経線維腫症、または肝細胞癌である、[9]に記載の方法。
[11] 前記増殖性疾患が、B−Raf変異によって特徴付けられる、[10]に記載の方法。
[12] 前記増殖性疾患が、B−RafV600変異によって特徴付けられる、[10]に記載の方法。
[13] 前記増殖性疾患が、メラノーマまたは大腸がんである、[12]に記載の方法。
[14] [1]、[2]または[3]のいずれかに記載の組合せ医薬を含む、組合せ製剤。
[15] [1]、[2]または[3]のいずれかに記載の組合せ医薬を含む、医薬組成物。
Claims (12)
- 同時、個別または逐次投与のための、
(a)式
のCDK4/6阻害剤またはその薬学的に許容される塩と、
(b)式
のB−Raf阻害剤またはその薬学的に許容される塩と
を含む、治療を必要としている対象における増殖性疾患の治療において使用するための、または、増殖性疾患の治療のための薬剤の調製において使用するための、組合せ医薬。 - MEK1/2阻害剤をさらに含む、請求項1に記載の組合せ医薬。
- 前記MEK1/2阻害剤が、式
の化合物またはその薬学的に許容される塩である、請求項2に記載の組合せ医薬。 - 前記増殖性疾患が、メラノーマ、肺がん(非小細胞肺がん(NSCLC)を含む)、大腸がん(CRC)、乳がん、腎がん、腎細胞癌(RCC)、肝がん、急性骨髄性白血病(AML)、骨髄異形成症候群(MDS)、甲状腺がん、膵がん、神経線維腫症、または肝細胞癌である、請求項1〜3のいずれか一項に記載の組合せ医薬。
- 前記増殖性疾患が、B−Raf変異によって特徴付けられる、請求項4に記載の組合せ医薬。
- 増殖性疾患の治療のための薬剤の製造のための、
(a)式
のCDK4/6阻害剤またはその薬学的に許容される塩と、
(b)式
のB−Raf阻害剤またはその薬学的に許容される塩と
を含む組合せ医薬の使用。 - 前記増殖性疾患が、メラノーマ、肺がん、大腸がん(CRC)、乳がん、腎がん、腎細胞癌(RCC)、肝がん、急性骨髄性白血病(AML)、骨髄異形成症候群(MDS)、非小細胞肺がん(NSCLC)、甲状腺がん、膵がん、神経線維腫症、または肝細胞癌である、請求項6に記載の使用。
- 前記増殖性疾患が、B−Raf変異によって特徴付けられる、請求項7に記載の使用。
- 前記増殖性疾患が、B−RafV600変異によって特徴付けられる、請求項7に記載の使用。
- 前記増殖性疾患が、メラノーマまたは大腸がんである、請求項9に記載の使用。
- 請求項1〜5のいずれか一項に記載の組合せ医薬を含む、組合せ製剤。
- 請求項1〜5のいずれか一項に記載の組合せ医薬を含む、医薬組成物。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261676134P | 2012-07-26 | 2012-07-26 | |
US61/676,134 | 2012-07-26 | ||
US201361830911P | 2013-06-04 | 2013-06-04 | |
US61/830,911 | 2013-06-04 | ||
PCT/US2013/051990 WO2014018725A1 (en) | 2012-07-26 | 2013-07-25 | Pharmaceutical combinations of a cdk4/6 inhibitor and a b-raf inhibitor |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2015523397A JP2015523397A (ja) | 2015-08-13 |
JP2015523397A5 JP2015523397A5 (ja) | 2016-08-25 |
JP6320379B2 true JP6320379B2 (ja) | 2018-05-09 |
Family
ID=48917729
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015524444A Active JP6320379B2 (ja) | 2012-07-26 | 2013-07-25 | Cdk4/6阻害剤およびb−raf阻害剤の組合せ医薬 |
Country Status (16)
Country | Link |
---|---|
US (1) | US9700557B2 (ja) |
EP (1) | EP2877174B1 (ja) |
JP (1) | JP6320379B2 (ja) |
KR (1) | KR102113363B1 (ja) |
CN (1) | CN104507474B (ja) |
AR (1) | AR091876A1 (ja) |
AU (1) | AU2013295771B2 (ja) |
CA (1) | CA2874860C (ja) |
ES (1) | ES2778059T3 (ja) |
HK (1) | HK1210721A1 (ja) |
IN (1) | IN2015DN00376A (ja) |
JO (1) | JO3776B1 (ja) |
MX (1) | MX360045B (ja) |
RU (1) | RU2685250C2 (ja) |
TW (1) | TWI599357B (ja) |
WO (1) | WO2014018725A1 (ja) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2934515B1 (en) * | 2012-12-20 | 2018-04-04 | Novartis AG | A pharmaceutical combination comprising binimetinib |
ES2798899T3 (es) * | 2013-02-25 | 2020-12-14 | Novartis Ag | Mutación novedosa del receptor de andrógenos |
MA38522A1 (fr) | 2013-03-21 | 2017-10-31 | Novartis Ag | Thérapie de combinaison comprenant un inhibiteur de b-raf et un second inhibiteur. |
CN107205933A (zh) * | 2014-12-23 | 2017-09-26 | 米伦纽姆医药公司 | Raf抑制剂与aurora激酶抑制剂的组合 |
CN105753869B (zh) * | 2015-04-01 | 2018-09-25 | 苏州晶云药物科技有限公司 | 一种cdk抑制剂和mek抑制剂的共晶及其制备方法 |
WO2016155670A1 (zh) * | 2015-04-01 | 2016-10-06 | 苏州晶云药物科技有限公司 | 一种cdk抑制剂和mek抑制剂的共晶及其制备方法 |
JP2018526377A (ja) * | 2015-08-28 | 2018-09-13 | ノバルティス アーゲー | がんを治療するための、任意にpi3k阻害剤のbyl719を更に含む、cdk4/6阻害剤のlee011とmek1/2阻害剤トラメチニブの組み合わせ物 |
CN105732642B (zh) * | 2015-11-18 | 2018-09-25 | 苏州晶云药物科技有限公司 | 一种cdk抑制剂和mek抑制剂的共晶及其制备方法 |
UA125436C2 (uk) * | 2016-06-03 | 2022-03-09 | Еррей Біофарма, Інк. | Фармацевтичні комбінації |
JP7190425B2 (ja) * | 2016-08-23 | 2022-12-15 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 肝細胞癌の治療のための併用療法 |
WO2018051306A1 (en) * | 2016-09-19 | 2018-03-22 | Novartis Ag | Therapeutic combinations comprising a raf inhibitor and a erk inhibitor |
WO2018081211A1 (en) * | 2016-10-26 | 2018-05-03 | Li George Y | Deuterated 7-cyclopentyl-n, n-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7h-pyrrolo[2,3-d]pyrimdine-6-carboxamide |
US11395821B2 (en) | 2017-01-30 | 2022-07-26 | G1 Therapeutics, Inc. | Treatment of EGFR-driven cancer with fewer side effects |
US11266653B2 (en) * | 2017-05-02 | 2022-03-08 | Novartis Ag | Combination therapy |
WO2019136451A1 (en) | 2018-01-08 | 2019-07-11 | G1 Therapeutics, Inc. | G1t38 superior dosage regimes |
AU2019220746A1 (en) | 2018-02-15 | 2020-08-27 | Nuvation Bio Inc. | Heterocyclic compounds as kinase inhibitors |
WO2019195959A1 (en) * | 2018-04-08 | 2019-10-17 | Cothera Biosciences, Inc. | Combination therapy for cancers with braf mutation |
US11633401B2 (en) | 2018-07-06 | 2023-04-25 | Memorial Sloan Kettering Cancer Center | Combination therapy with MEK inhibitor and CDK4/6 inhibitor to treat pancreatic cancer |
MX2021007477A (es) * | 2018-12-20 | 2021-08-05 | Novartis Ag | Terapia de combinacion con un inhibidor de raf y un inhibidor de cdk4/6 para utilizar en el tratamiento del cancer. |
TW202114667A (zh) * | 2019-09-11 | 2021-04-16 | 大陸商江蘇恒瑞醫藥股份有限公司 | Mek抑制劑與cdk4/6抑制劑聯合在製備治療腫瘤的藥物中的用途 |
CN115551509A (zh) * | 2020-05-12 | 2022-12-30 | 诺华股份有限公司 | 包含craf抑制剂的治疗组合 |
WO2023230554A1 (en) | 2022-05-25 | 2023-11-30 | Pfizer Inc. | Combination of a braf inhibitor, an egfr inhibitor, and a pd-1 antagonist for the treatment of braf v600e-mutant, msi-h/dmmr colorectal cancer |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100984613B1 (ko) * | 2002-03-13 | 2010-09-30 | 어레이 바이오파마 인크. | Mek 억제제로서의 n3 알킬화 벤즈이미다졸 유도체 |
US7235537B2 (en) * | 2002-03-13 | 2007-06-26 | Array Biopharma, Inc. | N3 alkylated benzimidazole derivatives as MEK inhibitors |
JP2007530654A (ja) * | 2004-03-30 | 2007-11-01 | ファイザー・プロダクツ・インク | シグナル伝達阻害剤の組合せ |
CA2729914A1 (en) | 2008-07-11 | 2010-01-14 | Novartis Ag | Combination of (a) a phosphoinositide 3-kinase inhibitor and (b) a modulator of ras/raf/mek pathway |
CN102186856B (zh) * | 2008-08-22 | 2014-09-24 | 诺华股份有限公司 | 作为cdk抑制剂的吡咯并嘧啶化合物 |
JO3002B1 (ar) * | 2009-08-28 | 2016-09-05 | Irm Llc | مركبات و تركيبات كمثبطات كيناز بروتين |
RU2589696C2 (ru) * | 2010-04-13 | 2016-07-10 | Новартис Аг | КОМБИНАЦИЯ, ВКЛЮЧАЮЩАЯ ИНГИБИТОР ЦИКЛИНЗАВИСИМОЙ КИНАЗЫ 4 ИЛИ ЦИКЛИНЗАВИСИМОЙ КИНАЗЫ 6 (CDK4/6) И ИНГИБИТОР mTOR, ДЛЯ ЛЕЧЕНИЯ РАКА |
-
2013
- 2013-07-24 AR ARP130102621A patent/AR091876A1/es not_active Application Discontinuation
- 2013-07-25 KR KR1020157001594A patent/KR102113363B1/ko active IP Right Grant
- 2013-07-25 JP JP2015524444A patent/JP6320379B2/ja active Active
- 2013-07-25 MX MX2015001122A patent/MX360045B/es active IP Right Grant
- 2013-07-25 AU AU2013295771A patent/AU2013295771B2/en active Active
- 2013-07-25 IN IN376DEN2015 patent/IN2015DN00376A/en unknown
- 2013-07-25 RU RU2015106524A patent/RU2685250C2/ru active
- 2013-07-25 ES ES13745540T patent/ES2778059T3/es active Active
- 2013-07-25 WO PCT/US2013/051990 patent/WO2014018725A1/en active Application Filing
- 2013-07-25 JO JOP/2013/0223A patent/JO3776B1/ar active
- 2013-07-25 EP EP13745540.8A patent/EP2877174B1/en active Active
- 2013-07-25 US US14/414,998 patent/US9700557B2/en active Active
- 2013-07-25 CA CA2874860A patent/CA2874860C/en active Active
- 2013-07-25 CN CN201380039725.5A patent/CN104507474B/zh active Active
- 2013-07-25 TW TW102126726A patent/TWI599357B/zh active
-
2015
- 2015-11-27 HK HK15111684.1A patent/HK1210721A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
RU2015106524A (ru) | 2016-09-20 |
AU2013295771B2 (en) | 2016-08-11 |
RU2685250C2 (ru) | 2019-04-17 |
ES2778059T3 (es) | 2020-08-07 |
KR20150036146A (ko) | 2015-04-07 |
CN104507474B (zh) | 2018-01-02 |
TWI599357B (zh) | 2017-09-21 |
US9700557B2 (en) | 2017-07-11 |
AU2013295771A1 (en) | 2014-12-11 |
TW201412316A (zh) | 2014-04-01 |
US20150164897A1 (en) | 2015-06-18 |
HK1210721A1 (en) | 2016-05-06 |
WO2014018725A1 (en) | 2014-01-30 |
JP2015523397A (ja) | 2015-08-13 |
JO3776B1 (ar) | 2021-01-31 |
EP2877174A1 (en) | 2015-06-03 |
CN104507474A (zh) | 2015-04-08 |
MX360045B (es) | 2018-10-19 |
CA2874860C (en) | 2020-06-23 |
BR112014033118A2 (pt) | 2017-06-27 |
AR091876A1 (es) | 2015-03-04 |
BR112014033118A8 (pt) | 2023-01-31 |
MX2015001122A (es) | 2015-04-08 |
IN2015DN00376A (ja) | 2015-06-12 |
CA2874860A1 (en) | 2014-01-30 |
KR102113363B1 (ko) | 2020-05-21 |
EP2877174B1 (en) | 2020-01-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6320379B2 (ja) | Cdk4/6阻害剤およびb−raf阻害剤の組合せ医薬 | |
JP6742391B2 (ja) | 併用療法 | |
US20210260059A1 (en) | Mdm2 inhibitors and combinations thereof | |
US20180243304A1 (en) | Pharmaceutical combinations comprising (a) the cyclin dependent kinase 4/6 (cdk4/6) inhibitor lee011 (=ribociclib), and (b) the epidermal growth factor receptor (egfr) inhibitor erlotinib, for the treatment or prevention of cancer | |
AU2013343425A1 (en) | Pharmaceutical combination comprising a B-Raf inhibitor and a histone deacetylase inhibitor and their use in the treatment of proliferative diseases | |
CN105848682A (zh) | 药物组合 | |
JP2019511526A (ja) | がんの処置のための、Notch阻害剤およびCDK4/6阻害剤の併用療法 | |
JP2017519019A (ja) | mdm2阻害剤の間欠投与 | |
JP2016529285A (ja) | 細胞増殖性疾患を治療するためのalk阻害剤とcdk阻害剤との組合せ | |
WO2016025648A1 (en) | Combinations of an erk inhibitor and a raf inhibitor and related methods | |
BR112014033118B1 (pt) | Combinações farmacêuticas de um inibidor de cdk4/6 e um inibidor de braf, e seus usos | |
WO2016025639A1 (en) | Combinations of an erk inhibitor and a chemotherapeutic agent and related methods | |
WO2023044065A1 (en) | Jak inhibitor with erk1/2 and/or shp2 inhibitors combination therapy | |
US20180256557A1 (en) | Pharmaceutical combination comprising (a) the alpha-isoform specific pi3k inhibitor alpelisib (byl719) and (b) an akt inhibitor, preferably mk-2206, afuresertib or uprosertib, and the use thereof in the treatment/prevention of cancer | |
EA040191B1 (ru) | Комбинированная терапия | |
WO2016025656A1 (en) | Combinations of an erk inhibitor and a pi3k inhibitor or dual pi3k/tor inhibitor and related methods |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160706 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20160706 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170404 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20170704 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20170904 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20171107 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180206 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20180306 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20180403 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6320379 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |